Patents by Inventor John S. Tyhonas
John S. Tyhonas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067626Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.Type: ApplicationFiled: June 26, 2023Publication date: February 29, 2024Inventors: Xiaohu S. OUYANG, Toufike KANOUNI, John S. TYHONAS, Jason M. COX, Robert S. KANIA
-
Patent number: 11753395Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.Type: GrantFiled: December 14, 2022Date of Patent: September 12, 2023Assignee: KINNATE BIOPHARMA INC.Inventors: Xiaohu S. Ouyang, Toufike Kanouni, John S. Tyhonas, Jason M. Cox, Robert S. Kania
-
Publication number: 20230219929Abstract: Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.Type: ApplicationFiled: December 14, 2022Publication date: July 13, 2023Inventors: Xiaohu S. OUYANG, Toufike KANOUNI, John S. TYHONAS, Jason M. COX, Robert S. KANIA
-
Patent number: 7176224Abstract: Novel compounds that are modulators of PPAR receptors, and pharmaceutically acceptable salts, solvates and hydrates thereof, processes for making the compounds, pharmaceutical compositions containing the compounds, or pharmaceutically acceptable salts, solvates and hydrates thereofType: GrantFiled: August 23, 2001Date of Patent: February 13, 2007Assignee: Eli Lilly and CompanyInventors: Robert J Ardecky, Dawn Alisa Brooks, Alexander Glenn Godfrey, Sarah Beth Jones, Nathan Bryan Mantlo, James Ray McCarthy, Pierre Yves Michellys, Christopher John Rito, John S Tyhonas, Leonard Larry Winneroski, Yanping Xu
-
Publication number: 20040248919Abstract: The present invention relates to a method of modulating retinoid X receptor activity in a mammal, novel compounds and pharmaceutical compositions for modulating retinoid X receptor activity in a mammal, and methods of making compounds that modulate retinoid X receptor activity in a mammal. The compounds are represented by Structural Formula 1: The compounds of Structural Formual 1 are efficacious insulin sensitizers and do not have the undesirable side effects of increasing triglycerides or suppressing the thyroid hormone axis.Type: ApplicationFiled: April 15, 2004Publication date: December 9, 2004Inventors: Michael Gregory Bell, Timothy Alan Grese, Douglas Linn Gernett, Nathan P. Yumibe, Marcus F. Boehm, Pierre-Yves Michellys, Robert J. Ardecky, Christopher M Mapes, Jyun-Hung Chen, John S. Tyhonas, Lawrence G. Hamann
-
Patent number: 6825222Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or uType: GrantFiled: May 7, 2003Date of Patent: November 30, 2004Assignees: Eli Lilly and Company, Ligand Pharmaceuticals, Inc.Inventors: Dawn A. Brooks, Christopher J. Rito, Anthony J. Shuker, Samuel J. Dominianni, Alan M. Warshawsky, Lynn S. Gossett, Donald P. Matthews, David A. Hay, Robert J. Ardecky, Pierre-Yves Michellys, John S. Tyhonas
-
Publication number: 20040138277Abstract: 1Type: ApplicationFiled: July 29, 2003Publication date: July 15, 2004Inventors: Robert J Ardecky, Dawn Alisa Brooks, Alexander Glenn Godfrey, Sarah Beth Jones, Nathan Bryan Mantlo, James Ray McCarthy, Pierre Yves Michellys, Christopher John Rito, John S Tyhonas, Leonard Larry Winneroski, Yanping Xu
-
Publication number: 20040049072Abstract: The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.Type: ApplicationFiled: May 9, 2003Publication date: March 11, 2004Inventors: Robert J. Ardecky, Marcus F. Boehm, Amy L. Faulkner, Lawrence G. Hamann, Todd K. Jones, Christopher M. Mapes, Pierre-Yves Michellys, John S. Tyhonas
-
Publication number: 20040019090Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: 1Type: ApplicationFiled: May 7, 2003Publication date: January 29, 2004Applicants: Eli Lilly & Company, Ligand Pharmaceuticals, Inc.Inventors: Dawn A. Brooks, Christopher J. Rito, Anthony J. Shuker, Samuel J. Dominianni, Alan M. Warshawsky, Lynn S. Gossett, Donald P. Matthews, David A. Hay, Robert J. Ardecky, Pierre-Yves Michellys, John S. Tyhonas
-
Patent number: 6610696Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or uType: GrantFiled: April 11, 2002Date of Patent: August 26, 2003Assignees: Eli Lilly and Company, Ligand Pharmaceuticals, Inc.Inventors: Dawn A. Brooks, Christopher J. Rito, Anthony J. Shuker, Samuel J. Dominianni, Alan M. Warshawsky, Lynn S. Gossett, Donald P. Matthews, David A. Hay, Robert J. Ardecky, Pierre-Yves Michellys, John S. Tyhonas
-
Patent number: 6593493Abstract: The present invention provides a novel class of RXR modulator compounds that exhibit an improved pharmacologic profile relative to the profile of previously studied RXR modulators, including those that share common structural features with the presently claimed modulators. The present invention also provides synthetic methods for preparing these compounds as well as pharmaceutical compositions incorporating these novel compounds and methods for the therapeutic use of such compounds and pharmaceutical compositions.Type: GrantFiled: September 14, 2000Date of Patent: July 15, 2003Assignee: Ligand Pharmaceuticals, Inc.Inventors: Robert J. Ardecky, Marcus F. Boehm, Amy L. Faulkner, Lawrence G. Hamann, Todd K. Jones, Christopher M. Mapes, Pierre-Yves Michellys, John S. Tyhonas, Anthony W. Thompson, Jyun-Hung Chen
-
Publication number: 20030045558Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: 1Type: ApplicationFiled: April 11, 2002Publication date: March 6, 2003Applicant: Eli Lilly & Company Lily Corporate CenterInventors: Dawn A. Brooks, Christopher J. Rito, Anthony J. Shuker, Samuel J. Dominianni, Alan M. Warshawsky, Lynn S. Gossett, Donald P. Matthews, David A. Hay, Robert J. Ardecky, Pierre-Yves Michellys, John S. Tyhonas
-
Patent number: 6417212Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or uType: GrantFiled: August 23, 2000Date of Patent: July 9, 2002Assignees: Eli Lilly & Company, Ligand Pharmaceuticals, Inc.Inventors: Dawn A. Brooks, Christopher J. Rito, Anthony J. Shuker, Samuel J. Dominianni, Alan M. Warshawsky, Lynn S. Gossett, Donald P. Matthews, David A. Hay, Robert J. Ardecky, Pierre-Yves Michellys, John S. Tyhonas